
News|Articles|December 8, 2010
ASH 2010 Homepage Header
Advertisement
Oncology NEWS International reports on critical information from the American Society of Hematology's 52nd annual meeting.
- Rituximab instead of ‘watch and wait’ policy in asymptomatic follicular lymphoma causes controversy
- Ofatumumab generates high response rates in refractory CLL
- Industry update: Early-stage trials establish pathways for new treatment agents
- More Coverage from ASH 2010
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer
2
Omitting Sentinel Lymph Node Biopsy Is Safe in Select Patients With HR+ Early Breast Cancer
3
ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia
4
FDA Grants National Priority Voucher to Teclistamab/Daratumumab in RRMM
5
















































































